Catalent Completes $30 Million Project for Biopharmaceutical Development and Manufacturing in Limoges, France

Published on: 

Catalent has announced the completion of a $30 million project at its facility in Limoges, France focused on biopharmaceutical development and drug product manufacturing.

Catalent announced on March 16, 2022 that a $30 million (€27 million) project at its facility in Limoges, France has been completed. The project focused on biopharmaceutical development, drug product fill/finish services, and packaging.

The project has modernized the Limoges site to support large molecule programs and increase capacity for small molecule injectable dosage form development. The expansion includes the installation of a new small-to-mid-scale flexible filling line, which is able to handle vials, syringes, or cartridges under barrier isolator technology. Enhancements to analytical and quality control laboratories have also been included, which supports clinical packaging, cold storage, and regulatory capabilities.

The Limoges site will expand Catalent Biologics’ global network with early-phase integrated clinical development and small-scale commercial manufacturing, which will be able to transfer to late-stage and larger-scale commercial supply from its other facilities in Europe and North America progressively. The site is also anticipated to add up to 80 additional jobs through the expansion.


“This investment has transformed the Limoges site into a world-class facility to support the development of early phase and small-scale commercial biologic drugs, and offers customers integrated services to accelerate programs towards and through the clinic, and ultimately to market,” commented Mike Riley, Catalent’s president, Biotherapeutics, in the press release.“Even prior to completion, multiple clinical and commercial customers have already signed contracts for programs to be undertaken at the site. Limoges will now work closely with other Catalent facilities in Europe and the US to provide globally integrated solutions for a range of therapies.”

Source: Catalent